安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

交易中 07-22 11:13:07 EDT

103.34

+1.49

+1.46%

最高103.39	最低99.86	成交量13.28万
今开102.84	昨收101.85	日振幅3.47%
总市值36.84亿	流通市值17.72亿	总股本3,565万
成交额1,349万	换手率0.77%	流通股本1,714万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":103.335,"timestamp":1721661183731,"preClose":101.85,"halted":0,"volume":132839,"delay":0,"floatShares":17144660,"shares":35647164,"eps":32.08883,"marketStatus":"交易中","marketStatusCode":2,"change":1.485,"latestTime":"07-22 11:13:07 EDT","open":102.84,"high":103.39,"low":99.86,"amount":13493011.16863,"amplitude":0.034659,"askPrice":103.37,"askSize":69,"bidPrice":103.21,"bidSize":144,"shortable":3,"etf":0,"ttmEps":32.08883,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"adjPreClose":101.85,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":102.88,"preClose":101.85,"latestTime":"09:10 EDT","volume":6449,"amount":657502.89376,"timestamp":1721653843777},"postHourTrading":{"tag":"盘后","latestPrice":102.01,"preClose":101.85,"latestTime":"19:58 EDT","volume":15142,"amount":1543603.993,"timestamp":1721433491968},"volumeRatio":1.151761,"impliedVol":0.8467,"impliedVolPercentile":0.9562},"requestUrl":"/m/hq/s/CAR","defaultTab":"news","newsList":[{"id":"2453279694","title":"安飞士跌1.82% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2453279694","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453279694?lang=zh_cn&edition=full","pubTime":"2024-07-22 21:59","pubTimestamp":1721656767,"startTime":"0","endTime":"0","summary":"北京时间2024年07月22日21时59分，安飞士股票出现异动，股价大幅下跌1.82%。截至发稿，该股报100.00美元/股，成交量6.6694万股，换手率0.19%，振幅2.85%。安飞士股票所在的租赁服务行业中，整体涨幅为0.08%。其相关个股中，Zoomcar Holdings Inc C/Wts 31/05/2025 、Flexshopper, Inc.、威利斯金融租赁涨幅较大，Zoomcar Holdings, Inc.、赫兹租车、安飞士较为活跃，换手率分别为0.30%、0.21%、0.19%，振幅较大的相关个股有Multi Ways Holdings Limited、赫兹租车、Vestis Corporation，振幅分别为12.29%、6.04%、3.60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407222159289681ee7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407222159289681ee7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2452281332","title":"削减CAR-NK资产 美国Caribou裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=2452281332","media":"贝果财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452281332?lang=zh_cn&edition=full","pubTime":"2024-07-20 05:18","pubTimestamp":1721423889,"startTime":"0","endTime":"0","summary":"本报记者 张悦 曹学平 北京报道美国生物技术公司驯鹿生物(Caribou Biosciences，CRBU.US，以下简称“Caribou”)近日宣布，将削减CAR-NK资产，并裁员21人，占员工总数的12%。公告显示，公司正在进行此次削减，以扩大其现金流，并将资源集中在其异体CAR-T细胞治疗平台和快速推进的四个肿瘤和自身免疫性疾病临床项目上。随后，...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240720A00LU600","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240720A00LU600","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2452840220","title":"安飞士盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452840220","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452840220?lang=zh_cn&edition=full","pubTime":"2024-07-20 02:07","pubTimestamp":1721412446,"startTime":"0","endTime":"0","summary":"北京时间2024年07月20日02时07分，安飞士股票出现波动，股价快速跳水5.12%。截至发稿，该股报103.56美元/股，成交量15.4581万股，换手率0.43%，振幅4.53%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为1.36%。安飞士公司简介：Avis Budget Group Inc 是一家汽车租赁和汽车共享服务提供商。公司品牌包括 Avis、Budget 和 Zipcar。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407200207269681e96c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407200207269681e96c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4022","BK4230","CAR"],"gpt_icon":0},{"id":"2451612019","title":"核心CAR-T产品去年销售额达5亿美元，传奇生物收到并购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2451612019","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451612019?lang=zh_cn&edition=full","pubTime":"2024-07-15 18:17","pubTimestamp":1721038647,"startTime":"0","endTime":"0","summary":"传奇生物方面并未就此作出公开回应。截至2023年12月31日的年度业绩报告中，传奇生物公布，在2023年第四季度，CARVYKTI实现了全球销售额1.59亿美元，同比增长194%。目前，全球共获批上市 8 款 CAR-T 细胞治疗产品，其中有2款是BCMA CAR-T 疗法，一款是传奇生物的CARVYKTI，另一款是BMS旗下的Abecma。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/235038","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4505","BK4230","BK4139","BK4585","BK4588","CAR","BK4022","LEGN"],"gpt_icon":0},{"id":"2450368296","title":"安飞士涨2.44% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2450368296","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450368296?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:31","pubTimestamp":1720704711,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日21时31分，安飞士股票出现异动，股价快速上涨2.44%。截至发稿，该股报101.43美元/股，成交量1.0753万股，换手率0.03%，振幅1.76%。安飞士股票所在的租赁服务行业中，整体涨幅为0.80%。其相关个股中，赫兹租车、Alta Equipment Group Inc.、安飞士涨幅较大，Zoomcar Holdings, Inc.、The Aarons Co Inc 、Multi Ways Holdings Limited较为活跃，换手率分别为0.19%、0.17%、0.11%，振幅较大的相关个股有赫兹租车、Ftai Aviation Ltd.、安飞士，振幅分别为2.78%、1.76%、1.76%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112131519f34e011&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112131519f34e011&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2450040958","title":"安飞士跌2.33% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2450040958","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450040958?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:34","pubTimestamp":1720532092,"startTime":"0","endTime":"0","summary":"北京时间2024年07月09日21时34分，安飞士股票出现异动，股价大幅下挫2.33%。截至发稿，该股报99.64美元/股，成交量1.438万股，换手率0.04%，振幅1.06%。安飞士股票所在的租赁服务行业中，整体跌幅为0.63%。安飞士公司简介：Avis Budget Group Inc 是一家汽车租赁和汽车共享服务提供商。公司品牌包括 Avis、Budget 和 Zipcar。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407092134529681b273&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407092134529681b273&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2449776263","title":"首款BCMA靶向CAR-T疗法获批一周年，驯鹿生物获信达生物入股，商业化下半场怎么走？","url":"https://stock-news.laohu8.com/highlight/detail?id=2449776263","media":"时代财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449776263?lang=zh_cn&edition=full","pubTime":"2024-07-08 18:52","pubTimestamp":1720435947,"startTime":"0","endTime":"0","summary":"本文来源：时代财经  作者：张羽岐  在CAR-T细胞疗法伊基奥仑赛注射液（商品名：福可苏）获批一周年之际，驯鹿生物与信达生物（01801.HK）就该产品再次达成合作。驯鹿生物7月5日披露称，公司将按照约定价格购买信达生物在原BCMA CAR-T合作协议项下拥有的相关权益；同时，信达生物将按照相同价格入股驯鹿生物，入股后将持有...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240708A07W3Q00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240708A07W3Q00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["01801","LU2328871848.SGD","BK4022","BK1583","BK1589","CAR","BK1161","LU1969619763.USD","BK4230"],"gpt_icon":0},{"id":"2448143278","title":"Cartesian Therapeutics(RNAC.US)潜在“first-in-class“CAR-T疗法积极临床结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2448143278","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448143278?lang=zh_cn&edition=full","pubTime":"2024-07-03 10:07","pubTimestamp":1719972439,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Cartesian Therapeutics今天宣布了其在研mRNA细胞疗法Descartes-08在全身性重症肌无力患者中的2b期临床试验的积极顶线结果。在这项2b期双盲、安慰剂对照、交叉试验中，共有36名症状严重、经过大量治疗的MG患者被随机分配(1：1)接受每周一次门诊输注Descartes-08或安慰剂治疗共6周，患者不进行预处理化疗。在试验的第3个月盲性评估结束后，接受安慰剂的患者有资格转为接受Descartes-08治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4230","BK4139","CAR","RNAC","BK4022"],"gpt_icon":0},{"id":"2448146133","title":"强生(JNJ.US)/传奇生物(LEGN.US)CAR-T疗法3期取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2448146133","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448146133?lang=zh_cn&edition=full","pubTime":"2024-07-03 10:03","pubTimestamp":1719972232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月3日，强生与传奇生物共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺耐药的多发性骨髓瘤患者。Carvykti是获批用于多发性骨髓瘤患者二线或以上治疗的首个B细胞成熟抗原靶向CAR-T疗法。BCMA主要表达于恶性多发性骨髓瘤B细胞、晚期B细胞和浆细胞的表面。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","LU0795875169.SGD","LEGN","BK4550","LU1023059063.AUD","BK4505","LU1221951046.USD","LU1244550494.USD","LU1032466523.USD","SG9999002232.USD","SG9999002224.SGD","BK4585","LU2347655156.SGD","LU1430594728.SGD","LU0889566641.SGD","JNJ","LU1267930813.SGD","LU1732800096.USD","LU2602419157.SGD","BK4592","BK4022","LU0912757837.SGD","BK4504","LU1196500208.SGD","SG9999001440.SGD","BK4588","LU0640476718.USD","LU1506573853.SGD","LU1162221912.USD","LU1074936037.SGD","LU1244550577.SGD","BK4139","BK4568","LU0795875086.SGD","IE00BSNM7G36.USD","CAR","LU1059921491.USD","LU0114720955.EUR","IE00B19Z3581.USD","LU0234572021.USD","LU1032955483.USD","IE00B7SZLL34.SGD","LU1244550221.USD","LU1066053197.SGD","LU0466842654.USD","LU1585245621.USD","BK4559","LU2133065610.SGD","LU1935042991.SGD","LU1221951129.SGD"],"gpt_icon":0},{"id":"2446384771","title":"港股异动 | 石药集团(01093)涨超3% 首款基于mRNA-LNP的CAR-T细胞注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446384771","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446384771?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:41","pubTimestamp":1719373306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团(01093)涨超3%，截至发稿，涨3.15%，报6.55港元，成交额2亿港元。消息面上，石药集团公布，集团开发的首款基于mRNA-LNP的嵌合抗原受体(CAR)-T细胞注射液(SYS6020）已获国家药监局批准，可在中国开展临床试验。本次获批的临床适应症为多发性骨髓瘤（MM）。此外，该产品潜在可用于治疗系统性红斑狼疮（SLE）、重症肌无力（MG）等自身免疫疾病。据悉，该产品为全球首款获批临床试验的基于mRNA-LNP的细胞治疗产品。临床前研究显示，该产品可显著杀伤BCMA抗原阳性的骨髓瘤细胞，并具有良好的安全性和有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","LU0880133367.SGD","SG9999004220.SGD","LU0067412154.USD","LU0501845795.SGD","LU1807302812.USD","LU1993786604.SGD","BK1521","IE00B543WZ88.USD","BK1576","LU0326950275.SGD","LU0072913022.USD","BK1583","CAR","LU1226287529.USD","BK4022","BK1191","LU0140636845.USD","BK4230","03347","HSCEI","07226","YANG","01093","BK1515","IE0008368742.USD","HSTECH","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2446188848","title":"石药集团公告称 首款基于mRNA-LNP的CAR-T细胞注射液(SYS6020) 获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446188848","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446188848?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:47","pubTimestamp":1719308835,"startTime":"0","endTime":"0","summary":"每经AI快讯，6月25日，石药集团公告称，首款基于mRNA-LNP的CAR-T细胞注射液(SYS6020)获临床试验批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406253113223951.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406253113223951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","LU0880133367.SGD","SG9999004220.SGD","LU0067412154.USD","LU0501845795.SGD","LU1807302812.USD","LU1993786604.SGD","IE00B543WZ88.USD","BK1521","BK1576","LU0326950275.SGD","LU0072913022.USD","BK1583","CAR","LU1226287529.USD","BK4022","BK1191","LU0140636845.USD","BK4230","03347","01093","BK1515","IE0008368742.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2446776897","title":"石药集团(01093)：首款基于mRNA-LNP的CAR-T细胞注射液(SYS6020)获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446776897","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446776897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:43","pubTimestamp":1719308595,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的首款基于mRNA-LNP的嵌合抗原受体-T细胞注射液(该产品)已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床试验的基于mRNA-LNP的细胞治疗产品。通过表达可特异性识别BCMA抗原的CAR，进而靶向识别患者体内BCMA阳性的细胞并对其进行杀灭，从而达到治疗目的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4022","BK1521","CAR","LU1807302812.USD","BK1583","LU0072913022.USD","LU1993786604.SGD","LU0501845795.SGD","BK1576","SG9999004220.SGD","IE00B543WZ88.USD","BK1191","LU0326950275.SGD","IE00B5MMRT66.SGD","03347","LU0067412154.USD","01093","BK4230","BK1515","LU0140636845.USD","BK1141","LU0880133367.SGD","IE0008368742.USD","LU1226287529.USD"],"gpt_icon":0},{"id":"2444412314","title":"自免新贵CAR-T的“命门”","url":"https://stock-news.laohu8.com/highlight/detail?id=2444412314","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444412314?lang=zh_cn&edition=full","pubTime":"2024-06-19 12:58","pubTimestamp":1718773103,"startTime":"0","endTime":"0","summary":"十多年来，CAR-T疗法一直是肿瘤学界的宠儿，尤其在治疗血癌方面取得了显著的成功。目前，CAR-T疗法主要针对的是血液肿瘤中的B细胞肿瘤。因此，CAR-T疗法在肿瘤学和免疫学之间的转换是合理的，并且市场对此也有所预期。核心在于，在一些早期探索中，CAR-T疗法在自免领域的安全性和疗效得到了兼顾。日前，因为1例患者复发，自免CAR-T新贵Kyverna的股价，在短短两个交易日内腰斩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/233790","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2444358994","title":"美国 CAR-MART 公司公布截至四月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2444358994","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444358994?lang=zh_cn&edition=full","pubTime":"2024-06-18 21:52","pubTimestamp":1718718758,"startTime":"0","endTime":"0","summary":"   * 美国 CAR-MART 公司    公布了截至 4 月份的季度调整后每股收益 6 美分，低于去年同期的每股收益 32 美分。四位分析师对该季度的平均预期是每股收益 89 美分。* America's CAR-MART Inc 公布的本季度每股收益为 6 美分。* 公司报告的季度净收入为 41.6 万美元。* America's CAR-MART Inc 本季度股价下跌了 3.3%，今年迄今为止下跌了 18.5%。* 在过去的 30 天里，没有覆盖该公司的分析师对盈利预期进行修正。华尔街对 America's CAR-MART Inc 的 12 个月目标价中位数为 68.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MART","BK4230","BK4022","BK4214","CAR","CRMT"],"gpt_icon":0},{"id":"2444212221","title":"Mustang Bio(MBIO.US)暴涨近480%！公布CAR-T疗法MB-106最新积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2444212221","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444212221?lang=zh_cn&edition=full","pubTime":"2024-06-18 12:10","pubTimestamp":1718683808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物制药公司Mustang Bio周一收盘暴涨476.92%，报0.75美元。消息面上，Mustang Bio公布了其CAR-T细胞疗法MB-106治疗Waldenstrom巨球蛋白血症的1/2期试验的积极数据。该公司表示，数据显示，整体缓解率为90%，有一名患者在31个月后完全缓解，所有参加试验的10名患者之前都接受过BTKi疗法的治疗。Mustang Bio指出，目前美国食品药品管理局还没有批准针对Waldenstrom巨球蛋白血症的CAR-T细胞疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4230","MBIO","BK4139","BK4022","CAR"],"gpt_icon":0},{"id":"2444498991","title":"极低剂量有望带动CAR-T降价，“莱芒生物”再获5000万元天使轮次融资｜36氪首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2444498991","media":"36氪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444498991?lang=zh_cn&edition=full","pubTime":"2024-06-18 08:02","pubTimestamp":1718668933,"startTime":"0","endTime":"0","summary":"文｜胡香赟编辑｜海若镜36氪获悉，莱芒生物近期完成总计5000万元的天使+轮和天使++轮融资，本轮融资新股东包括富汇创投、云帆科技投资及私人财务投资者，老股东天图投资、晶泰科技持续加码；公司另获约2000万元的各类资助。2021年成立至此，莱芒生物累计获得约1.5亿元天使融资及资助。本次募集资金将用于公司“极低剂量”代...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OxpJTXmwSd4l67827CSaBswX5e7paYIlLXGkOAos_8VwAAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OxpJTXmwSd4l67827CSaBswX5e7paYIlLXGkOAos_8VwAAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240618A00XNW00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240618A00XNW00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2443679677","title":"欧盟监管机构强制要求更新 CAR-T 癌症疗法的标签","url":"https://stock-news.laohu8.com/highlight/detail?id=2443679677","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443679677?lang=zh_cn&edition=full","pubTime":"2024-06-14 22:45","pubTimestamp":1718376323,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月14日 - 欧洲卫生监管机构周五表示， ，一类被称为CAR-T疗法的癌症疗法的产品信息将被要求强调使用该疗法的患者罹患继发性癌症的风险，从而结束了为期五个月的安全审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0234570918.USD","LU2133065610.SGD","IE00B19Z3581.USD","JNJ","BK4550","GILD","LU1506573853.SGD","LU0466842654.USD","BK4585","LU1066053197.SGD","LU0640476718.USD","LU1935042991.SGD","BK4588","BK4559","CAR","BK4568","SG9999002224.SGD","SG9999002232.USD","LU0109394709.USD","LU2602419157.SGD","LU1059921491.USD","LU0795875169.SGD","LU0114720955.EUR","LU1221951129.SGD","LU1430594728.SGD","LU1221951046.USD","LU0889565916.HKD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4230","LU1032466523.USD","BK4592","BK4007","BK4139","LU1571399168.USD","BK4578","LU1839511570.USD","BK4583","LU1196500208.SGD","LU2087621335.USD","LU1244550221.USD","LU1032955483.USD","LU1244550494.USD","LU1162221912.USD","BK4022","LU0889566641.SGD","LU1280957306.USD","IE00BKVL7J92.USD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2443057675","title":"与癌症的漫长斗争中，CAR-T疗法行至何处？","url":"https://stock-news.laohu8.com/highlight/detail?id=2443057675","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443057675?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:15","pubTimestamp":1718266521,"startTime":"0","endTime":"0","summary":"你可能在许多地方读过小女孩艾米莉与CAR-T的故事，如今她已无癌生存多年。在此之前，人类与癌症的漫长斗争中，还没有出现过哪一种药物能如此真实地带来治愈的希望。CAR-T疗法也由此在血液瘤领域，大杀四方。那么，CAR-T疗法的探索之旅，究竟行至何处？其中CAR-T研究占比超过1/3。带给艾米莉“奇迹”的CAR-T疗法是Kymriah，也是全球第一款获批的CAR-T疗法。如今，全球共有11款CAR-T细胞疗法产品获批上市，其中5款为国内上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/233543","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2442552326","title":"安飞士盘中异动 早盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442552326","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442552326?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:38","pubTimestamp":1718199503,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时38分，安飞士股票出现波动，股价快速上涨5.06%。截至发稿，该股报109.54美元/股，成交量1.7111万股，换手率0.05%，振幅2.00%。安飞士股票所在的租赁服务行业中，整体涨幅为3.76%。其相关个股中，赫兹租车、联合租赁、安飞士涨幅较大，Zoomcar Holdings, Inc.、赫兹租车、联合租赁较为活跃，换手率分别为0.23%、0.16%、0.07%，振幅较大的相关个股有赫兹租车、Hertz Global Holdings Inc C/Wts 30/06/2051 、联合租赁，振幅分别为5.65%、5.43%、3.73%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061221382496813b5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061221382496813b5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2442898720","title":"2023全球细胞和基因疗法营收Top10","url":"https://stock-news.laohu8.com/highlight/detail?id=2442898720","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442898720?lang=zh_cn&edition=full","pubTime":"2024-06-10 07:49","pubTimestamp":1717976970,"startTime":"0","endTime":"0","summary":"近日，GEN杂志报道了2023年全球最畅销细胞和基因疗法Top10榜单(不含反义寡核苷酸(ASO)疗法)。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/source/image/26507.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/26507.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ASO","BK4022","BK4230","BK4561","CAR","BK4200"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0245},{"period":"3month","weight":0.002},{"period":"6month","weight":-0.3797},{"period":"1year","weight":-0.5573},{"period":"ytd","weight":-0.4254}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家在特拉华州成立，总部位于新泽西州帕西帕尼市的公司。艾维士·巴吉集团为全球企业和消费者提供汽车和卡车租赁和配套服务。该公司经营着两家全球汽车租赁行业中最知名的品牌Avis和Budget。 Avis是一家领先的汽车租赁供应商，定位于服务旅游业的优质商业和休闲领域，而Budget是一家领先的汽车租赁供应商，业务主要集在该行业中更具价值意识的部分。该公司是领先的汽车租赁运营商，在北美，澳大利亚，新西兰和其他地区都有业务服务，该公司授权在世界各地以Avis和Budget品牌经营的国家就有超过180个多个。该公司通常在机场汽车租赁收入中占有主要份额，并运营着美国主要的卡车租赁业务之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.012765},{"month":2,"riseRate":0.642857,"avgChangeRate":0.055699},{"month":3,"riseRate":0.642857,"avgChangeRate":0.042142},{"month":4,"riseRate":0.642857,"avgChangeRate":0.012091},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.006618},{"month":6,"riseRate":0.5,"avgChangeRate":0.008098},{"month":7,"riseRate":0.571429,"avgChangeRate":0.042992},{"month":8,"riseRate":0.461538,"avgChangeRate":0.008638},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037867},{"month":10,"riseRate":0.769231,"avgChangeRate":0.153852},{"month":11,"riseRate":0.692308,"avgChangeRate":0.064181},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.03046}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}